HGEN लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (5 Jan 2024 @ 00:15):

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'...

Stats
आज की मात्रा	2.06M
औसत मात्रा	341 846
बाजार मूल्य	23 816.00
EPS	$0 ( 2024-03-28 )
अगली कमाई की तारीख	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.000392
ATR14	$0.00100 (1 000.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-18	Chappell Dale	Sell	276 210	Common Stock, $0.001 par value
2023-10-18	Chappell Dale	Sell	75 887	Common Stock, $0.001 par value
2023-10-18	Chappell Dale	Sell	34 253	Common Stock, $0.001 par value
2022-07-27	Buxton Cheryl	Buy	78 362	Stock Option (Right to Buy)
2022-07-27	Hohneker John	Buy	63 195	Stock Option (Right to Buy)

INSIDER POWER
36.18
Last 98 transactions
Buy: 5 830 886 \| Sell: 2 957 610

मात्रा सहसंबंध

लंबा: 0.10 (neutral)

छोटा: 0.00 (neutral)

Signal:(38.548) Neutral

Humanigen, Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Humanigen, Inc. सहसंबंध - मुद्रा/वस्त्र

-0.64
( weak negative )

-0.68
( moderate negative )

0.00
( neutral )

0.02
( neutral )

0.41
( neutral )

Humanigen, Inc. वित्तीय

Annual	2022
राजस्व:	$2.51M
सकल लाभ:	$2.51M (100.00 %)
EPS:	$-1.180

FY	2022
राजस्व:	$2.51M
सकल लाभ:	$2.51M (100.00 %)
EPS:	$-1.180

FY	2021
राजस्व:	$3.60M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-3.98

FY	2020
राजस्व:	$312 000
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-2.42

Financial Reports:

No articles found.

Humanigen, Inc.

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.